Jeffrey Linton - Sequenom Sr. VP and General Counsel
SVP
Mr. Jeffrey D. Linton J.D. is Senior Vice President General Counsel and Secretary of the Company since September 2014. Before joining Sequenom Mr. Linton was Senior Vice President and General Counsel at Beckman Coulter Inc. from July 2011 to September 2014. Prior to that he was Vice President Deputy General Counsel from September 2008 to July 2011. Before joining Beckman Coulter Mr. Linton was President of the research products and services division of Serologicals Corporation a company that developed manufactured and sold life science research products and technologies diagnostic kits and drug discovery services. Before that role he served as Vice President Corporationrationrate Business Development and General Counsel at Serologicals from October 2000 to April 2003. He has held various other positions in law government and public affairs and human resources since 2014.
| Age | 50 |
| Tenure | 10 years |
| Phone | 858 202-9000 |
| Web | www.sequenom.com |
Sequenom Management Efficiency
The company has return on total asset (ROA) of (0.1133) % which means that it has lost $0.1133 on every $100 spent on assets. This is way below average. Sequenom's management efficiency ratios could be used to measure how well Sequenom manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 132.69 M in liabilities with Debt to Equity (D/E) ratio of 6.82, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sequenom has a current ratio of 3.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sequenom until it has trouble settling it off, either with new capital or with free cash flow. So, Sequenom's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sequenom sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sequenom to invest in growth at high rates of return. When we think about Sequenom's use of debt, we should always consider it together with cash and equity.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women health and oncology markets in the United States and internationally. Sequenom (SQNM) is traded on NASDAQ Exchange in USA and employs 434 people. Management Performance
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -0.11 |
Sequenom Leadership Team
Elected by the shareholders, the Sequenom's board of directors comprises two types of representatives: Sequenom inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sequenom. The board's role is to monitor Sequenom's management team and ensure that shareholders' interests are well served. Sequenom's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sequenom's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Slacik, Independent Director | ||
| Dirk Boom, CEO and President Director and Member of Science Committee | ||
| Kenneth Buechler, Independent Director | ||
| Catherine Mackey, Director | ||
| Robin Weiner, Senior Vice President - Quality and Regulatory Affairs | ||
| Richard Lerner, Lead Independent Director | ||
| Daniel Grosu, Senior Vice President and Chief Medical Officer | ||
| Carolyn Beaver, CFO, Chief Accounting Officer, Vice President | ||
| MBA Tatman, Sr. VP of Bus. Devel. | ||
| Ronald Lindsay, Director | ||
| David Pendarvis, Independent Director | ||
| Myla LaiGoldman, Director | ||
| Jeffrey Linton, Sr. VP and General Counsel | ||
| Donna Nichols, IR Contact Officer |
Sequenom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sequenom a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.12) % | |||
| Operating Margin | (28.68) % | |||
| Current Valuation | 279.54 M | |||
| Shares Outstanding | 118.22 M | |||
| Shares Owned By Insiders | 0.92 % | |||
| Shares Owned By Institutions | 51.80 % | |||
| Number Of Shares Shorted | 9.79 M | |||
| Price To Earning | 12.08 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Sequenom Stock
If you are still planning to invest in Sequenom check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sequenom's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |